Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral proteins interact with the eukaryotic translation machinery, and inhibitors of translation have potent antiviral effects. We found that the drug plitidepsin (aplidin), which has limited clinical approval, possesses antiviral activity...

Descripción completa

Detalles Bibliográficos
Autores principales: White, Kris M., Rosales, Romel, Yildiz, Soner, Kehrer, Thomas, Miorin, Lisa, Moreno, Elena, Jangra, Sonia, Uccellini, Melissa B., Rathnasinghe, Raveen, Coughlan, Lynda, Martinez-Romero, Carles, Batra, Jyoti, Rojc, Ajda, Bouhaddou, Mehdi, Fabius, Jacqueline M., Obernier, Kirsten, Dejosez, Marion, Guillén, María José, Losada, Alejandro, Avilés, Pablo, Schotsaert, Michael, Zwaka, Thomas, Vignuzzi, Marco, Shokat, Kevan M., Krogan, Nevan J., García-Sastre, Adolfo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7963220/
https://www.ncbi.nlm.nih.gov/pubmed/33495306
http://dx.doi.org/10.1126/science.abf4058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7963220/
https://www.ncbi.nlm.nih.gov/pubmed/33495306
http://dx.doi.org/10.1126/science.abf4058

Ejemplares similares